

1 **Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or**
2 **vector-based COVID-19 vaccinations**

3 Henning Jacobsen^{#,1}, Monika Strengert^{#,2,3}, Henrike Maaß^{*,1}, Mario Alberto Ynga Durand^{*,1},
4 Barbora Kessel², Manuela Harries², Ulfert Rand¹, Leila Abassi¹, Yeonsu Kim¹, Tatjana
5 Lüddecke¹, Pilar Hernandez², Julia Ortmann², Jana-Kristin Heise², Stefanie Castell², Daniela
6 Gorny², Stephan Glöckner², Vanessa Melhorn², Berit Lange^{2,5}, Alex Dulovic⁴, Julia Häring⁴,
7 Daniel Junker⁴, Nicole Schneiderhan-Marra⁴, Markus Hoffmann^{6,7}, Stefan Pöhlmann^{6,7}, Gérard
8 Krause^{2,3,5,§}, Luka Cicin-Sain^{1,5,8,§}

9 1 Helmholtz Centre for Infection Research, Department of Viral Immunology, Braunschweig,
10 Germany

11 2 Helmholtz Centre for Infection Research, Department of Epidemiology Braunschweig,
12 Germany

13 3 TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture of the
14 Hannover Medical School and the Helmholtz Centre for Infection Research, Hannover,
15 Germany

16 4 NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen,
17 Germany

18 5 German Centre for Infection Research (DZIF), partner site Hannover-Braunschweig, Germany

19 6 Deutsches Primatenzentrum, Leibniz-Institut für Primatenforschung, Göttingen, Germany

20 7 Faculty of Biology and Psychology, Georg-August-University Göttingen, Germany

21 8 Centre for Individualized Infection Medicine (CIIM), a joint venture of Helmholtz Centre for
22 Infection Research and Medical School Hannover, Germany

23
24 # (first authors), * (second authors), § (corresponding authors): these authors contributed
25 equally.

26
27 Corresponding authors contact details:
28 Luka Cicin-Sain, Phone number: +49 (0)53161814616, Email address: [luka.cicin-](mailto:luka.cicin-sain@helmholtz-hzi.de)
29 [sain@helmholtz-hzi.de](mailto:luka.cicin-sain@helmholtz-hzi.de), Postal address: Inhoffenstraße 7, 38124 Braunschweig, Germany.

30
31

32 **Abstract**

33 *Background:* SARS-CoV-2 variants accumulating immune escape mutations provide a
34 significant risk to vaccine-induced protection. The novel variant of concern Omicron (B.1.1.529)
35 has to date the largest number of amino acid alterations in its Spike protein. Thus, it may
36 efficiently escape recognition by neutralizing antibodies, allowing breakthrough infections in
37 convalescent and vaccinated individuals.

38 *Aims:* We analysed neutralization activity of all mRNA-, vector- or heterologous immunization
39 schemes currently approved in Europe at peak response and in a longitudinal follow-up with
40 BNT162b2 vaccinees to define immune escape potential of the Omicron VoC.

41 *Methods:* We tested sera by *in vitro* pseudotype particle neutralization assay towards SARS-
42 CoV-2 B.1, Omicron, Beta and Delta Spike proteins.

43 *Results:* All vaccines apart from Ad26.CoV2.S showed high levels of responder rates (93-100%)
44 towards SARS-CoV-2 wild-type, but some reductions in neutralizing Beta and Delta VoC
45 pseudotypes. The novel Omicron variant had the biggest impact, both in terms of response
46 rates and neutralization titres among responders. Only mRNA-1273 showed a 100% response
47 rate to Omicron and induced the highest titres of neutralizing antibodies, followed by
48 heterologous prime-boost approaches. Homologous BNT162b2 vaccination or vector-based
49 formulations with AZD1222 or Ad26.CoV2.S performed less well with peak responder rates of
50 33%, 50% and 9%, respectively. However, Omicron responder rates in BNT162b2 recipients
51 were maintained in our six month longitudinal follow-up and even slightly increased to 47%,
52 indicating Omicron cross-protection is maintained over time.

53 *Conclusions:* Our data strongly argues for urgent booster doses particularly for those who were
54 previously vaccinated with BNT162b2 or a vector-based immunization scheme.

55 **Keywords**

56 SARS-CoV-2, Omicron, B.1.1.529, variants of concern, protective immunity, neutralization,
57 COVID-19 vaccination

58

59

60 Introduction

61 Since its emergence in late 2019, SARS-CoV-2 has caused a pandemic with more than 270
62 million confirmed infections and more than 5 million deaths[1]. While a series of vaccines have
63 been developed with unprecedented speed and were successfully deployed to limit the burden
64 of COVID-19, it became quickly apparent that novel SARS-CoV-2 variants had evolved, mainly
65 in areas of high virus prevalence. Those have accumulated mutations in the surface-exposed
66 Spike protein, which increase virus transmissibility or promote evasion from the host immune
67 response[2-4]. Immune escape was most pronounced in SARS-CoV-2 variants Beta (B.1.351)
68 and the currently globally dominating Delta (B.1.617.2), at least until recently. However, the
69 November 2021 emergence of the variant B.1.1.529 (Omicron) in South Africa has raised strong
70 concerns as its unusually high number of amino acid alterations in the Spike protein will likely
71 contribute to an increased reinfection risk or breakthrough infections following vaccination[5]. By
72 now, a series of studies using samples from convalescent and vaccinated individuals have
73 addressed the impact of Omicron on vaccination or infection-induced antibody neutralization,
74 using either live-, pseudovirus neutralization or *in vitro* binding assays[6-14]. These studies have
75 shown clear losses of neutralization capacity against the Omicron variant but did not
76 comprehensively address antibody responses in various vaccination regimens or over time. In
77 contrast, we provide here a comprehensive assessment of vaccination schemes approved in
78 the European Union and the UK, using an Omicron, Beta, Delta or wild-type (B.1) pseudo-
79 neutralization assay at peak response after approximately four weeks and in a longitudinal six
80 month follow-up for BNT162b2.

81 Methods

82 *Sample collection*

83 Serum samples analyzed in this study originate from vaccinated participants of the multi-local
84 and serial cross-sectional prevalence study on antibodies against SARS-CoV-2 in Germany
85 (MuSPAD) study, a population-based SARS-CoV-2 seroprevalence study in eight regions of
86 Germany from July 2020 to August 2021. The study was approved by the Ethics Committee of
87 the Hannover Medical School (9086_BO_S_2020) and was in line with the Declaration of
88 Helsinki. Briefly, MuSPAD is a successive cross-sectional study where certain locations were
89 sampled longitudinally within a 3-4 month interval [15]. Recruitment of eligible participants (>18
90 years) was based on age- and sex-stratified random sampling with information provided by the
91 respective local residents' registration offices. Basic sociodemographic data and information on
92 pre-existing medical conditions including a previous SARS-CoV-2 infection or vaccination are
93 self-reported and were documented with eResearch system PIA (Prospective Monitoring and
94 Management-App) at the study center. Peripheral blood was obtained by venipuncture using a
95 serum gel S-Monovette (Sarstedt) and further processed according to the manufacturer's
96 instructions. Serum was then aliquoted at the German Red Cross Institute of Transfusion
97 Medicine and Immunohematology and transported on dry ice to the Hannover Unified Biobank
98 for long-term storage.

99 For this study, we selected 82 samples from the available sample pool to contain mRNA, vector-
100 and heterologous immunization schemes at peak response and if available for a paired six
101 month follow-up with BNT162b2 only. None of the donors reported a positive SARS-CoV-2
102 antigen or PCR test result and were non-reactive for nucleocapsid-specific IgG, excluding
103 confounders due to infections superposed on vaccination in our cohort. Vaccination details with
104 basic sociodemographic information and pre-existing conditions such as hypertension,
105 cardiovascular disease, diabetes, lung disease, immunosuppression or cancer of participants
106 are provided in Table 1 and Supplementary Table S1. As controls, the first WHO International
107 Standard for human anti-SARS-CoV-2 immunoglobulin (code: 20/136) from the National
108 Institute for Biological Standards and Control (NIBSC) or pre-pandemic sera samples from an
109 anonymized Hepatitis A and Influenza virus vaccination response study at the Helmholtz Centre
110 for Infection Research in 2014 (Hannover Medical School Ethics Committee approval number
111 2198-2021) were used.

112 *Cell culture*

113 Vero E6 (ATCC CRL-1586), and 293T (DSMZ ACC-635) were maintained in DMEM medium
114 supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin and
115 100 µg/ml streptomycin at 37 °C in a 5% CO₂ atmosphere. All cell lines used within this study
116 were below a passage of 50 and were regularly checked for mycoplasma contamination.
117 Transfection of 293T cells was performed using calcium-phosphate.

118 *Plasmids*

119 Plasmids encoding SARS-CoV-2 Spike B.1 (human codon optimized, 18 amino acid truncation
120 at C-terminus) and SARS-CoV-2 spike of Beta (B.1.351) and Delta (B.1.617.2) have been
121 previously reported [16-18]. The expression vector for SARS-CoV-2 Spike of Omicron (based
122 on isolate hCoV-19/Botswana/R40B58_BHP_3321001245/2021; GISAID Accession ID:
123 EPI_ISL_6640919) was generated by Gibson assembly [13]. An overview of mutations is
124 present in Supplementary Table S2. All plasmids were sequence-confirmed by Sanger
125 sequencing prior to use.

126 *Pseudotyping*

127 Generation of rhabdoviral pseudotypes harboring SARS-CoV-2 Spike proteins was performed
128 as described[19]. In brief, 293T cells were transfected with pCG1 plasmids expressing different
129 SARS-CoV-2 Spike proteins, using calcium-phosphate. 24 h post transfection, cells were
130 infected with a replication-deficient reporter VSV-G (VSV*ΔG-Fluc) at an MOI of 3 for 1 h at 37
131 °C [20]. Cells were washed once with PBS and medium containing anti-VSV-G antibody (culture
132 supernatant from L1-hybridoma cells) was added to neutralize residual input virus. The cell
133 culture supernatant was harvested after 16 hours, and cellular debris was removed by
134 centrifugation at 2.000 g for 5 min at 4 °C. Aliquots were stored at -80°C until use.

135 *Neutralization assay*

136 For pseudovirus neutralization, serum samples and controls were heat-inactivated at 56 °C for
137 30 min. Thawed samples and controls were stored at 4°C for no longer than 48 hours, prior to
138 use. In a 96-well microtiter plate, serum samples were 2-fold serially diluted in cell culture

139 medium (DMEM, 5 % FBS, 1% P/S, 1% L-Glu) with a dilution range of 1:10 to 1:5120. Pre-
140 diluted samples were incubated with an equal volume of Spike protein-bearing viral particles
141 (approx. 200 – 500 ffu/well) at 37 °C for 1 h. After incubation, the sample-virus mixture was
142 transferred to VeroE6 cells at 100% confluence which were seeded the day before. Cells were
143 incubated at 37 °C for 24±2 h and infected cells were visualized using an IncuCyte S3
144 (Sartorius) performing whole-well scans (4x) in phase contrast and green fluorescence settings.
145 Automated segmentation and fluorescent foci counting was performed using the IncuCyte GUI
146 software (versions 2019B Rev1 and 2021B) Raw data were plotted in GraphPad prism (v8) and
147 FRNT₅₀ was calculated with a variable slope, four parameter regression analysis. Non-
148 responders were defined as subjects with undetectable neutralization titers at an initial serum
149 dilution of 1:10. FRNT₅₀ values of those individuals were arbitrarily set to 1. All experiments
150 were performed with internal standard controls (pool of all tested sera), negative controls and
151 virus-only controls to assess the nominal virus input for every single measurement.

152 *Data analysis and statistics*

153 Initial results collation and matching to metadata was done in Excel 2016 and R 4.1.0. Graphs
154 and statistical calculations were performed using GraphPad Prism version 9.0.2 for Windows
155 (GraphPad Software). For analysis of neutralization assay results, a Shapiro-Wilk test was used
156 to determine normality. Focus Reduction Neutralization titre with a 50% neutralization cut-off
157 (FRNT₅₀) was calculated using a four-parameter regression analysis function. FRNT₅₀ values
158 from non-responders were set to 1.0 for graphical presentation only. A non-parametric
159 Friedman's test followed by Dunn's multiple comparison analysis was used to compare
160 neutralization results to different viruses in a pair-wise manner for matched samples. Two-tailed
161 Wilcoxon matched-pairs signed rank test was used to compare neutralization of longitudinal
162 results. A p-value of less than 0.05 was considered statistically significant.

163 **Results**

164 Neutralization responses towards B.1, B.1.1.529, B.1.351, and B.1.617.2 Spike-expressing
165 rhabdoviral pseudotypes were analysed in 82 serum samples from individuals vaccinated with
166 either a single dose of Ad26.COVS, homologous two-dose BNT162b2, mRNA-1273 or
167 AZD1222 vaccination, or heterologous AZD1222-BNT162b2 or AZD1222-mRNA-1273
168 vaccination at peak response, approximately four weeks after the last dose. The WHO
169 international standard serum showed detectable neutralization against all variants including
170 Omicron (Supplementary Table S3), showing excellent sensitivity of our assay, compared to
171 previous studies [21]. Pre-pandemic control sera (n=4) showed no measurable neutralization
172 levels (Supplementary Table S3). While neutralization potency towards Beta VoC pseudotypes
173 were clearly reduced for all vaccination schemes, Omicron had the strongest effect across all
174 samples tested (Fig. 1). Vaccination with vector-based Ad26.CoV2.S performed least well (Fig.
175 1a), with only 73% responders against the B.1 variant, 18% classified as responders for the
176 Beta VoC and 9% for Omicron. Homologous vaccination with either AZD1222 or BNT162b2
177 performed better against Omicron, with 50% or 33% responders, respectively (Fig. 1b, 1c).
178 Heterologous immunization with these two vaccines (AZD1222-BNT162b2) showed a response
179 rate of 80% (Fig. 1d). Heterologous vaccination with AZD1222-mRNA-1273 had a similar
180 response rate of 82% (Fig. 1e), but homologous immunization with mRNA-1273 had the highest

181 Omicron response rate of 100% (Fig. 1f). Non-responders were defined as subjects with
182 undetectable neutralization titers at an initial serum dilution of 1:10. Non-parametrical statistical
183 comparisons showed a highly significant reduction in serum titres when Omicron neutralization
184 was compared to B.1 for all vaccination schemes (Fig 1b-e).). There was no tendency of age,
185 sex, or pre-existing medical conditions to modify the responder status against Omicron in our
186 cohort (Supplementary Table S3). To assess the impact of immune escape with more detail, we
187 focused on the responders and compared geometric means of their FRNT₅₀ titres (GMT).
188 Importantly, fold-changes for groups that included non-responders are not provided in Fig. 1,
189 because this would lead to highly artificial results and possibly over-interpretation. We therefore
190 present the percentage of responders as primary outcome and provide fold-changes of GMT
191 where calculation is reasonable (100% responders in both arms). Furthermore, for each
192 vaccination regimen, we defined the responder subgroups (excluding non-responders in either
193 group) and compared the fold-reduction for titres that could be quantified (see Table 2). In these
194 subsets, we observed an approximate 15-fold reduction in GMT for most vaccinations, except
195 BNT162b2, where the reduction was 28-fold at peak responses. This was consistent with the
196 high frequency of non-responders in this subset, additionally arguing for weaker protection
197 against the Omicron variant in this cohort.

198 Since BNT162b2 is very commonly used, we tested the neutralization potency in BNT162b2
199 recipients at approximately six months post immunization as well. Similar to the peak
200 responses, we observed a significantly weaker neutralization of the Omicron compared to the
201 B.1 pseudotype and only 47% responders against the newly emerging VoC (Fig. 2a). Beta
202 neutralization was slightly reduced, whereas Delta neutralization was at same levels as B.1 at
203 the late time point (Fig. 2a). To understand the longitudinal dynamic of humoral immunity, we
204 used paired sera from BNT162b2 vaccine recipients at four weeks (already shown in Fig. 1c)
205 and at six months post second dose which allowed us to compare intra-individual titre changes
206 over time (Fig. 2b-d). While the neutralization of B.1 (Fig. 2b) and of the Delta VoC (Fig. 2d)
207 decreased significantly over time, the time dependent reduction was less pronounced for the
208 Beta (Fig 2c) or the Omicron VoC (Fig. 2e). Moreover, all Omicron responders identified early
209 after vaccination had still detectable neutralizing capacity at the late time points and two
210 additional responders were identified in the late phase only (Fig. 2e). Therefore, the differences
211 in neutralization titres between B.1 and Omicron responders were less pronounced at late time
212 points than at peak response (Table 2).

213 In sum, homologous mRNA-1273 vaccination resulted in the highest responder rate,
214 Ad26.CoV2.S in the lowest, and longitudinal follow-up showed that Omicron responses, while
215 reduced, seem rather durable if present in the first place.

216 Discussion

217 We provide a comprehensive overview of neutralization responses from all currently approved
218 COVID-19 vaccination schemes in the European Union and the UK not only towards the
219 Omicron VoC, but also towards Beta and Delta VoC compared to the parental strain B.1. We
220 expand on previous findings [11, 12] that neutralization towards Omicron is particular poor after
221 vaccination with vector-based formulations even within the peak phase shortly after vaccination.
222 Also consistent with other reports [13, 14], we observed a very low cross-neutralization in

223 BNT162b2 recipients. While our BNT162b2 samples had rather low neutralization titres overall,
224 there was no signal this was due to clear differences in group, age or comorbidities. Considering
225 our relatively small sample size, it is however possible that this low overall response in the
226 BNT162b2 group was a spurious observation. Nevertheless, the samples showing any cross-
227 neutralizing responses early on remained responsive to Omicron six months later. Notably, all
228 mRNA-1273 recipients and 80% of those receiving any heterologous vaccination showed a
229 detectable neutralization against Omicron in our analysis. It is not clear, why these vaccination
230 protocols were more efficient against the Omicron pseudotype than BNT162b2, but it is
231 indicative that the baseline neutralization against the B.1 pseudotype was stronger in all of them
232 in our sample cohorts.

233 The detectable responsiveness to the Omicron pseudotype in all mRNA-1273 recipients differed
234 from previous reports where usually several samples showed no measurable neutralization
235 against Omicron [12, 14, 22]. This might be due to sampling differences, a result of increased
236 sensitivity in our assay, or both. We chose responder rates as primary outcome because this is
237 a less biased expression than fold changes if titres from non-responsive individuals are
238 calculated. For the same reason, we used a non-parametric assay to evaluate differences,
239 allowing us to include samples that were below detection threshold, but obviously very low in
240 titre. Fold changes were calculated separately on a subset of samples that showed detectable
241 titres in all circumstances. We observed an approximately 15-fold reduction in most vaccination
242 regimens except BNT162b2, adding evidence that Omicron cross-neutralization was impaired in
243 this cohort. While sample numbers in our cohort are low, they are comparable to the majority of
244 other studies to date and are well-matched on age and sex.

245 Following current recommendations, a booster vaccination is generally advised after six months.
246 Considering our results, booster vaccination might already be advised at earlier stages,
247 especially for risk groups in the absence of a precise and clinically relevant correlate of
248 protection.

249 Overall, we provide further evidence that that amino acid mutations accumulated in the
250 B.1.1.529 Spike protein serve to escape vaccine-induced protection. In the absence of
251 conclusive data on infectivity and disease severity, development of adapted second generation
252 vaccinations, booster doses and careful monitoring of future variants of concern appears
253 warranted.

254 **Funding**

255 This work was financially supported by the Initiative and Networking Fund of the Helmholtz
256 Association of German Research Centres through projects “Virological and immunological
257 determinants of COVID-19 pathogenesis – lessons to get prepared for future pandemics (KA1-
258 Co-02 “COVIPA”) to LCS and grant number SO-96 to GK, by the Deutsche
259 Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence
260 Strategy – EXC 2155 “RESIST” – Project ID 39087428 to LCS, and intramural funds of the
261 Helmholtz Centre for Infection Research. SP was supported by BMBF (01KI2006D,
262 01KI20328A, 01KX2021), the Ministry for Science and Culture of Lower Saxony (14-76103-184,
263 MWK HZI COVID-19) and the German Research Foundation (DFG; PO 716/11-1, PO 716/14-
264 1).

265 **Declaration of Interest**

266 NSM was a speaker at Luminex user meetings in the past. The Natural and Medical Sciences
267 Institute at the University of Tübingen is involved in applied research projects as a fee for
268 services with the Luminex Corporation. The other authors declare no competing interest.

269 **Acknowledgments**

270 We want to thank again all parties involved in any capacity in making MuSPAD happen. Most of
271 all the study participants for their willingness and commitment to make this study possible and
272 all colleagues at the HZI, the Hannover Unified Biobank and the DRK Institute of Transfusion
273 Medicine and Immunohematology who contributed to project administration, organization and
274 sample processing. We thank Daniela Lenz, Ayse Barut, Inge Hollatz-Rangosch and Fawad
275 Khan for excellent technical assistance during this study.

276 **Author contribution**

277 MS, HJ, LCS conceived the study. MS, GK, BL, SC, NSM, SP and LCS procured funding. GK,
278 BL, MS, MaH and DG designed the population-based cohort this study is based on. HJ, MS and
279 LCS designed the experiments. HJ, HM, MYD, UR, LA, YK and TL performed the experiments.
280 MHa, BK, MS, JH, MYD and HM performed data analysis. MS, HJ, HM, MYD generated figures
281 and tables. MS, BK, HJ, LCS verified the underlying data. MHo, SP provided reagents. AD, DJ,
282 JH, MS, BK, PH, BL, SC, MHa, DG, SG, JKH, VM were involved in sample or data collection
283 and project administration. MS, HJ, LCS wrote the manuscript. All authors critically reviewed
284 and approved the final manuscript.


285 **Data Sharing Statement**

286 Raw data is provided with the manuscript. Additional data is available upon request from the
287 corresponding authors.

288

289

290 **Figures**




291
292

293 **Figure 1. Impact of SARS-CoV-2 vaccination schemes on neutralization response**
294 **towards Omicron (B.1.1.529) variant.**

295 Vaccination-induced neutralization potency against Omicron (B.1.1.529), Beta (B. 1.351), Delta
296 (B.1.617.2) or Wuhan (B.1) pseudotypes was measured in individuals who received a vector-
297 based vaccination with single dose Ad26.CoV2.S (n=11, a), two doses of AZD1222 (n=14, b),
298 two doses of mRNA vaccine BNT162b2 (n=15, c), a heterologous two-dose vaccination with
299 AZD1222-BNT162b2 (n=15, d) or AZD1222-mRNA-1273 (n=11, e), or two doses of mRNA
300 vaccine mRNA-1273 (n=16, f) 21 to 61 days after the last dose. FRNT₅₀ data is expressed for
301 each serum sample, bold horizontal lines and whiskers are geometric means with 95% CI.
302 Interconnecting lines represent sample data from the same donor. Non-neutralizing sample
303 values were arbitrarily set to 1 for presentation purposes, indicated by a dashed line. Fold

304 change in neutralization potency between SARS-CoV-2 wild-type and VoC pseudotypes is
305 shown below p-values. Percentage (%) responder rates and FRNT₅₀ geometric mean titres
306 (GMT) per SARS-CoV-2 pseudotype are shown above the individual measurements. Fold
307 change in neutralization potency and GMTs for SARS-CoV-2 pseudotypes are only calculated
308 for groups where all samples had a detectable neutralizing activity, or else non-applicable (na)
309 is stated. Time between sampling and full vaccination in days is displayed as mean and SD
310 below the vaccination scheme. Statistical analysis was performed by paired non-parametric
311 Friedman's test followed by a Dunn's multiple comparison analysis. Statistical significance was
312 defined by a value of * < 0.05; ** < 0.01; *** < 0.001; **** < 0.0001.
313



314
315

316 **Figure 2. Longitudinal BNT162b2 neutralization response towards SARS-CoV-2 VoC**
317 **Omicron (B.1.1.529).**

318 Neutralization capacity towards SARS-CoV-2 Omicron (B.1.1.529), Beta (B. 1.351), Delta
319 (B.1.617.2) or Wuhan (B.1) pseudotypes was analysed approximately six months after a two-

320 dose BNT162b2 vaccination (n=15, a). Neutralization kinetic of paired longitudinal samples
321 towards SARS-CoV-2 B.1 (b), Beta (c), Delta (d) and Omicron (e) pseudotypes is shown
322 between T1 (n=15; mean (SD) ΔT after last dose: 28.3 (4.3)) and T2 (n=15; mean (SD) ΔT after
323 last dose: 173.6 (11.4)). Peak neutralization responses of BNT162b2-vaccinated individuals
324 from Figure 1c are displayed for clarity and comparison (b-e). FRNT₅₀ data is expressed for
325 each serum sample, bold horizontal lines and whiskers are geometric means with 95% CI.
326 Interconnecting lines represent sample data from the same donor (a-e). Non-neutralizing
327 samples were arbitrarily set to 1 for presentation purposes, indicated by a dashed line. Fold
328 change in neutralization potency between SARS-CoV-2 wild-type and VoC pseudotypes is
329 shown below p-values. Percentage (%) responder rates and FRNT₅₀ geometric mean titres
330 (GMT) per SARS-CoV-2 pseudotype are shown above the individual measurements. Fold
331 change in neutralization potency and GMTs for SARS-CoV-2 pseudotypes are only calculated
332 for groups where all samples had a detectable neutralizing activity, or else non-applicable (na)
333 is stated. Statistical analysis was performed by paired non-parametric Friedman's test followed
334 by a Dunn's multiple comparison analysis (a) or a by two-tailed Wilcoxon matched-pairs signed
335 rank test. Statistical significance was defined by a value of *<0.05; ** <0.01; ***<0.001;
336 ****<0.0001.
337
338

339 **Table 1. Sample characteristics** (na: not applicable)
 340

Sample cohort (n)	ΔT (days) post-complete vaccination (mean, SD)	ΔT (days) between doses (mean, SD)	Age (years), median (IQR)	Sex (n, %)	
				Female	Male
two-dose BNT162b2 T1* (15)	28.3 (4.8)	21.3 (1.2)	50 (39-56)	12 (80.0)	3 (20.0)
two-dose BNT162b2 T2* (15)	173.6 (11.4)		50 (40-57)		
two-dose mRNA-1273 (16)	28.5 (4.2)	32.0 (6.1)	56 (54-68)	11 (68.8)	5 (31.2)
first dose AZD1222, second dose mRNA-1273 (11)	28.2 (4.4)	65.4 (21.6)	68 (65-73)	7 (63.7)	4 (36.4)
first dose AZD1222, second dose BNT162b2 (15)	26.0 (4.1)	76.2 (7.7)	67 (65-69)	4 (26.7)	11 (73.4)
two-dose AZD1222 (14)	27.1 (1.2)	77.6 (1.8)	65 (63-69)	7 (50.0)	7 (50.0)
one-dose Ad26.CoV2.S (11)	55.3 (5.4)	na	61 (58-63)	7 (63.6)	4 (36.4)

* Two-dose BNT162b2 T1 and two-dose BNT162b2 T2* are paired longitudinal samples.

341 **Table 2. Geometric means of responses and fold changes in Omicron responder subsets**
 342

Vaccination regimen	GMT (95% CI) of paired <u>responders</u>			
	B.1	Beta	Delta	Omicron
two-dose mRNA-1273	526.0 (368.1-751.5)	119.6 (70.7-202.5)	481.5 (70.7-202.5)	33.2 (21.2-52.2)
first dose AZD1222, second dose BNT162b2	902.8 (572.0-1425.0)	173.9 (109.0-277.5)	173.9 (109.0-277.5)	61.5 (44.0-85.9)
first dose AZD1222, second dose mRNA-1273	1323.0 (740.6-2363.0)	368.9 (156.9-867.3)	923.8 (418.5-2039.0)	75.6 (41.2-138.9)
two-dose AZD1222	186.4 (91.2-381.3)	46.4 (20.8-103.5)	95.3 (41.5-232.9)	14.6 (7.0-30.5)
one-dose Ad26.CoV2.S*	na	na	na	na
two-dose BNT162b2 T1**	393.0 (213.5-723.6)	56.6 (14.3-223.5)	503.5 (275.2-921.0)	13.7 (7.8-24.1)
two-dose BNT162b2 T2**	82.6 (60.1-113.6)	31.3 (16.8-58.2)	85.7 (51.4-142.7)	10.9 (7.3-16.5)
Vaccination regimen	Fold-change in GMT of paired <u>responders</u>			
	B.1	Beta	Delta	Omicron
two-dose mRNA-1273	-	-4.4	-1.1	-15.8
first dose AZD1222, second dose BNT162b2	-	-5.2	-1.6	-14.7
first dose AZD1222, second dose mRNA-1273	-	-3.6	-1.4	-17.5
two-dose AZD1222	-	-4.0	-1.9	-12.8
one-dose Ad26.CoV2.S*	-	na	na	na
two-dose BNT162b2 T1**	-	-6.9	-0.8	-28.7
two-dose BNT162b2 T2**	-	-2.6	-1.0	-7.5

* Only one subject showed detectable neutralization titers in the Omicron assay.

** Two-dose BNT162b2 T1 and two-dose BNT162b2 T2 are paired longitudinal samples.

343

344 **References**

- 345 1. WHO. WHO Coronavirus (COVID-19) Dashboard 2021 [Available from: <https://covid19.who.int/>.
- 346 2. Altmann DM, Boyton RJ, Beale R. Immunity to SARS-CoV-2 variants of concern. *Science*.
347 2021;371(6534):1103-4.
- 348 3. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of
349 Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *N Engl J Med*. 2021;385(7):585-94.
- 350 4. Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, et al. The biological and
351 clinical significance of emerging SARS-CoV-2 variants. *Nat Rev Genet*. 2021;22(12):757-73.
- 352 5. WHO. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern 2021 [Available
353 from: [https://www.who.int/news/item/26-11-2021-classification-of-omicron-\(b.1.1.529\)-sars-cov-2-variant-of-concern](https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern).
- 354
- 355 6. Zhang L, Li Q, Liang Z, Li T, Liu S, Cui Q, et al. The significant immune escape of pseudotyped
356 SARS-CoV-2 Variant Omicron. *Emerg Microbes Infect*. 2021:1-11.
- 357 7. Cele S, Jackson L, Khan K, Khoury DS, Moyo-Gwete T, Tegally H, et al. SARS-CoV-2 Omicron has
358 extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for
359 infection. *medRxiv*. 2021.
- 360 8. Dejnirattisai W, Shaw RH, Supasa P, Liu C, Stuart AS, Pollard AJ, et al. Reduced neutralisation of
361 SARS-COV-2 Omicron-B. 1.1. 529 variant by post-immunisation serum. *medRxiv*. 2021.
- 362 9. Wilhelm A, Widera M, Grikscheit K, Toptan T, Schenk B, Pallas C, et al. Reduced Neutralization of
363 SARS-CoV-2 Omicron Variant by Vaccine Sera and Monoclonal Antibodies. *medRxiv*. 2021.
- 364 10. Schubert M, Bertoglio F, Steinke S, Heine PA, Ynga-Durand MA, Zuo F, et al. Human serum from
365 SARS-CoV-2 vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2
366 Omicron variant. *medRxiv*. 2021.
- 367 11. Schmidt F, Muecksch F, Weisblum Y, Silva JD, Bednarski E, Cho A, et al. Plasma neutralization
368 properties of the SARS-CoV-2 Omicron variant. *medRxiv*. 2021.
- 369 12. Rössler A, Riepler L, Bante D, Laer Dv, Kimpel J. SARS-CoV-2 B.1.1.529 variant (Omicron) evades
370 neutralization by sera from vaccinated and convalescent individuals. *medRxiv*. 2021.
- 371 13. Hoffmann M, Krüger N, Schulz S, Cossmann A, Rocha C, Kempf A, et al. The Omicron variant is
372 highly resistant against antibody-mediated neutralization – implications for control of the COVID-19
373 pandemic. *bioRxiv*. 2021.
- 374 14. Garcia-Beltran WF, St. Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, et al. mRNA-
375 based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant.
376 *medRxiv*. 2021.
- 377 15. Gorny D, Harries M, Glöckner S, Strengert M, Kerrinnes T, Heise J-K, et al. SARS-CoV-2
378 seroprevalence in Germany. *Deutsches Ärzteblatt international*. 2021.
- 379 16. Hoffmann M, Zhang L, Kruger N, Graichen L, Kleine-Weber H, Hofmann-Winkler H, et al. SARS-
380 CoV-2 mutations acquired in mink reduce antibody-mediated neutralization. *Cell Rep*.
381 2021;35(3):109017.
- 382 17. Hoffmann M, Arora P, Gross R, Seidel A, Hornich BF, Hahn AS, et al. SARS-CoV-2 variants B.1.351
383 and P.1 escape from neutralizing antibodies. *Cell*. 2021;184(9):2384-93 e12.
- 384 18. Brinkmann C, Hoffmann M, Lubke A, Nehlmeier I, Kramer-Kuhl A, Winkler M, et al. The
385 glycoprotein of vesicular stomatitis virus promotes release of virus-like particles from tetherin-positive
386 cells. *PLoS One*. 2017;12(12):e0189073.
- 387 19. Kleine-Weber H, Elzayat MT, Wang L, Graham BS, Muller MA, Drosten C, et al. Mutations in the
388 Spike Protein of Middle East Respiratory Syndrome Coronavirus Transmitted in Korea Increase
389 Resistance to Antibody-Mediated Neutralization. *J Virol*. 2019;93(2).

- 390 20. Berger Rentsch M, Zimmer G. A vesicular stomatitis virus replicon-based bioassay for the rapid
391 and sensitive determination of multi-species type I interferon. PLoS One. 2011;6(10):e25858.
- 392 21. Aggarwal A, Stella AO, Walker G, Akerman A, Milogiannakis V, Brilot F, et al. SARS-CoV-2
393 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to
394 viral variants of concern. medRxiv. 2021:2021.12.14.21267772.
- 395 22. Doria-Rose NA, Shen X, Schmidt SD, O'Dell S, McDanal C, Feng W, et al. Booster of mRNA-1273
396 Vaccine Reduces SARS-CoV-2 Omicron Escape from Neutralizing Antibodies. medRxiv.
397 2021:2021.12.15.21267805.
- 398
- 399

400 **Supplementary Material - Diminished neutralization responses towards SARS-CoV-2**
 401 **Omicron VoC after mRNA or vector-based COVID-19 vaccinations**

402 **Supplementary Table S1. Comorbidities of study participants (NA: not available; CVD:**
 403 **cardiovascular disease).**

404

Sample cohort (n)	Co-morbidities (n, %)	CVD (n, %)	Lung disease (n, %)	Diabetes (n, %)	Cancer (n, %)	Immune-suppression (n, %)	Hypertension (n, %)
two-dose BNT162b 2 T1* (15)	0:9 (64.3) 1:4 (28.6) 2:1 (7.1) >2: 0 (0) 1 NA	0(0)	1 (7.1)	0(0)	0(0)	0 (0)	5 (35.7)
two-dose BNT162b 2 T2* (15)	0: 8 (53.3) 1: 5 (33.3) 2: 2 (13.3) >2: 0 (0)	1 (6.7)	1 (6.7)	0(0)	0(0)	2 (13.3)	5 (33.4)
two-dose mRNA-1273 (16)	0: 12 (75) 1: 4 (25) 2: 0 (0) >2: 0 (0)	1 (6.3)	1 (6.3)	0 (0)	1 (6.3)	0 (0)	1 (6.3)
first dose AZD1222, second dose mRNA-1273 (11)	0: 7 (63.6) 1: 3 (27.3) 2: 1 (9.1) >2: 0 (0)	2 (18.2)	0 (0)	0 (0)	0 (0)	0 (0)	3 (27.3)
first dose AZD1222, second dose BNT162b 2 (15)	0: 8 (53.3) 1: 3 (20) 2: 3 (20) >2: 1 (6.7)	1 (6.7)	1 (6.7)	2 (13.3)	1 (6.7)	0 (0)	7 (46.7)
two-dose AZD1222 (14)	0: 7 (50.0) 1: 6 (42.9) 1: 1 (7.1) >2: 0 (0)	0 (0)	0 (0)	2 (14.3)	0 (0)	0 (0)	6 (42.9)
one-dose Ad26.CoV 2.S (11)	0: 7 (63.6) 1: 3 (27.3) 2: 0 (0) >2: 1 (9.1)	1 (9.1)	1 (9.1)	1 (9.1)	0 (0)	1 (9.1)	4 (36.4)

* Two-dose BNT162b2 T1 and two-dose BNT162b2 T2* are paired longitudinal samples.

405 **Supplementary Table S2.** Amino acid mutations of Spike proteins used for SARS-CoV-2
 406 pseudotype construction compared to the parental strain B.1. Shared mutations among the
 407 constructs are highlighted in bold.
 408

B.1.351 (Beta) (EPI_ISL_700428)	B.1.617.2 (Delta) (EPI_ISL_1921353)	B.1.1.529 (Omicron) (EPI_ISL_6640919)
	T19R	
		A67V
		69-70del
D80A		
		T95I
	G142D	G142D
		143-145del
	E156G	
	157-158del	
		N211del/L212I
		Ins214EPE
242-244del		
R246I		
		G339D
		S371L
		S373P
		S375F
K417N		K417N
		N440K
		G446S
	L452R	
		S477N
	T478K	T478K
E484K		E484A
		Q493R
		G496S
		Q498R
N501Y		N501Y
		Y505H
		T547K
D614G	D614G	D614G
		H655Y
		N679K
	P681R	P681H
A701V		
		N764K
		D796Y
		N856K
	D950N	
		Q954H
		N969K
		L981F

409